Meeting
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
Authors
Judy S. Wang
Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, FL
Judy S. Wang , Martin Gutierrez , Drew W. Rasco , Ignacio Melero Bermejo , John D. Powderly , Erika P. Hamilton , Michael Millward , Ana Maria Arance , Rafal Stec , Victor Moreno , Manish Sharma , Iwona A. Lugowska , Mark J. Shackleton , Sophia Frentzas , John Edward Janik , Tracy Liu , Irina Shapiro , Kerry Whalen , Jeffrey Alan Jones , Alexander I. Spira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT05117476
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2532)
DOI
10.1200/JCO.2023.41.16_suppl.2532
Abstract #
2532
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: John D. Powderly
Poster
2021 ASCO Annual Meeting
Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
First Author: Stéphane Champiat
Poster
2023 ASCO Annual Meeting
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
First Author: Hans Gelderblom
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed